Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 850.00 840.00 870.00 855.00 855.00 855.00 65,212 16:35:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.3 -9.7 -17.3 - 632

Maxcyte Share Discussion Threads

Showing 451 to 475 of 675 messages
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
DateSubjectAuthorDiscuss
03/2/2021
17:26
I see it is a very positive development as it appears to be readying the financial institutions for the NASDAQ listing. I would expect the market to creep upwards tomorrow to at least reach 700p !
multibagger
03/2/2021
17:15
..strengthens the Company's balance sheet ahead of listing on Nasdaq.
someuwin
03/2/2021
17:09
What’s it for?
trickydicky1
03/2/2021
17:09
Blimey! Never saw that coming! Further exciting times ahead.....
assagai
03/2/2021
16:54
Important things are that (i) its been done at a premium to the share price and (ii) its only a small portion of the share cap. COnfirms therefore that management has their heads screwed on correctly!
adamb1978
03/2/2021
16:53
Wow, that's not something you see everyday! Fantastic company, if only AIM had more like this...
74tom
03/2/2021
16:43
Raised at 700p - a 4.5% premium!
someuwin
03/2/2021
16:40
MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Announces GBP40 million (approx. $55 million(1) ) Subscription Led by New and Existing Healthcare Specialist Investors Subscription led by D1 Capital Partners, T. Rowe Price, ArrowMark Partners, Baron Capital Group and First Light Asset Management alongside existing investors Casdin Capital and Sofinnova Partners...
someuwin
03/2/2021
08:06
Cheers pob - excellent thread. Presents a very strong buy case.
someuwin
02/2/2021
18:43
Interesting thread... hTTps://twitter.com/Modelio_Sthlm/status/1356670013286023174
pob69
01/2/2021
09:12
Added 10k. Retirement fund. Actually post retirement fund..
assagai
26/1/2021
20:21
...Very good interview.
someuwin
26/1/2021
11:03
hTTps://www.lsegissuerservices.com/spark/MaxCyteInc/events/a2abb541-f9e2-43a5-8677-5b56222f89e9 you can watch todays conference presentation from maxcyte here. probably nothing new for us.
nimbo1
25/1/2021
19:01
MaxCyte @MaxCyte_info ยท1h Congratulations to our partner, @PrecisionBioSci, on the Notice of Allowance for a patent application covering PBCAR19B. http://bit.ly/2NAGP2k #CART #lymphoma #Tcells #cancer
someuwin
23/1/2021
20:58
Hi Russ Thanks, I saw that though had forgotten to go through it in detail! To be honest, I'm not so fussed about precisely what it might be worth given that assuming their technology doesnt get distrupted somehow then their installed base and picks and shovels business model should be resilient and continue to keep compounding with the industry growth. That compounding is usually powerful in generating shareholder value and given I'm up almost 4x on my investment already, I'll be loving every year of the growth!! I've sold a couple 10-baggers on the way up before and not intending to do so this time! Adam
adamb1978
23/1/2021
16:18
Thanks Adam. Some more valuation thoughts here from Sahara on twitter hTTps://threadreaderapp.com/thread/1352176987994001410.html
homebrewruss
23/1/2021
14:27
I ran a search for comps to use as a valuation basis for Maxcyte. Using the criteria: - Nasdaq lsited - healthcare - $20m - $100m revenues - >$500m market cap - sale growth of at least 20% last year and each of hte next 2 years ...it threw out 17 names and the median NTM EV/sales multiple was 28x. Only 2 of the 17 were less than 10x. Really shows what the potential is here if they can continue to grow this consistently at the say 25% CAGR which they've achieved over the last 5 years. If they continue that growth for another 5 years, then the share price here should logically be say 4x where it is today. Higher growth and that 4x goes up meaningfully too
adamb1978
21/1/2021
17:27
There are none as blind as those who will not see... Quite how you can be seriously talking down MXCT at this point is beyond me. I'd say the extremely positive Crispr/Vertex news in December has increased the likelihood of success considerably, hence the rising share price. Next read outs will be key of course, but it would be a big surprise if the first 8 patients treated were all practically cured by chance. Exhibit 8 of this excellent research note from May 2020 exemplifies the 3-5 year (from today's date) revenue potential. It appears to suggest that milestone payments represent around 10-20% of the commercial licensing value of a single product, so the $950m pre clinical milestone payments could represent between $5-10b of commercial phase revenues. Extraordinary. https://www.trinitydelta.org/wp-content/uploads/2020/05/MaxCyte-Outlook-200526.pdf
74tom
21/1/2021
15:54
Nimbo he's not resident, he goes from house to house.
assagai
21/1/2021
15:43
I agree but didn’t want to be accused of ramping by the resident troll - ha.
nimbo1
21/1/2021
15:36
@Nimbo1, I note earlier in the thread you say this could be a $10b company in the next 10 years if Crispr's CX0001 drug is approved & is a bellwether for the rest of the industry. I'd go as far as to say that a picks and shovels play on Crispr as good as MXCT is could potentially 100 bag from the current levels in time... http://moneygrower.co.uk/fevertree-100-bagger-stocks/ "What surprised me most was that the majority of the stocks in the study were not speculative in nature. There was not as many biotech, junior minors or oil exploration companies as I had imagined. Furthermore, the median market cap for each at the outset of Mayer’s study was $500m – hardly the size of speculative investments." If CTX001 alone is bringing in single digit royalties of between $40-80m per annum based on 2026 consensus sales of $1.3b and even 10% of the current clinically licensed programs are successful then the mind boggles at where this could go. It's not a stretch to claim that MXCT could be looking at annual revenues of $1b+ in the late 2020's which would be on huge gross margins. I would also bet that only around 1 in 500 US investors are aware of it right now, maybe even less than that...
74tom
21/1/2021
14:58
that video now on ggp share board , a good example for other shares
bunz3
21/1/2021
12:46
Added another 3600@670p...averaging up :) Trade yet to show !
multibagger
21/1/2021
12:31
Concur. This is a solid hold.
assagai
21/1/2021
12:13
Also Maxcyte is a globally significant business on aim - the market cap is currently tiny when judged again US peer group. When its on nasdaq the market cap will rise to a level that reflects its status at the core of the gene and cell therapy market... All one has to do is hold for a couple of years while remembering the choice to hold is taking an action! I said the same when the share price was £1.50... so im consistent!
nimbo1
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
ADVFN Advertorial
Your Recent History
LSE
MXCT
Maxcyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210420 19:25:14